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Abstract
Background: A significant component of the variation in cognitive disability that is observed in Duchenne muscular
dystrophy (DMD) is known to be under genetic regulation. In this study we report correlations between standardised
measures of intelligence and mutational class, mutation size, mutation location and the involvement of dystrophin isoforms.
Methods and Results: Sixty two male subjects were recruited as part of a study of the cognitive spectrum in boys with DMD
conducted at the Sydney Children’s Hospital (SCH). All 62 children received neuropsychological testing from a single clinical
psychologist and had a defined dystrophin gene (DMD) mutation; including DMD gene deletions, duplications and DNA
point mutations. Full Scale Intelligence Quotients (FSIQ) in unrelated subjects with the same mutation were found to be
highly correlated (r= 0.83, p= 0.0008), in contrast to results in previous publications. In 58 cases (94%) it was possible to
definitively assign a mutation as affecting one or more dystrophin isoforms. A strong association between the risk of
cognitive disability and the involvement of groups of DMD isoforms was found. In particular, improvements in the
correlation of FSIQ with mutation location were identified when a new classification system for mutations affecting the
Dp140 isoform was implemented.
Significance: These data represent one of the largest studies of FSIQ and mutational data in DMD patients and is among the
first to report on a DMD cohort which has had both comprehensive mutational analysis and FSIQ testing through a single
referral centre. The correlation between FSIQ results with the location of the dystrophin gene mutation suggests that the
risk of cognitive deficit is a result of the cumulative loss of central nervous system (CNS) expressed dystrophin isoforms, and
that correct classification of isoform involvement results in improved estimates of risk.
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Introduction
Duchenne muscular dystrophy (DMD) is a clinically heteroge-
neous disorder of at least 4 clinical subphenotypes characterised by
differences in the severity of muscle and brain dysfunction (Online
Mendelian Inheritance in Man (OMIM) 310200) [1]. Duchenne
de Boulogne first noted the presence of cognitive deficits in DMD
in his initial description of the disorder [2], an observation which
has been confirmed in many subsequent studies [3–5]. The
consistent finding in the DMD neuropsychological profile is a
reduction in mean FSIQ by approximately 1 standard deviation
with respect to the population mean; with a range of severity
from borderline neuropsychological deficits to severe intellectual
disability. The frequency of FSIQ,70 has been estimated to be in
the range of 19–35% of DMD cases, with 3% of patients having
moderate-severe intellectual disability (FSIQ,50) [4–6]. Several
studies have compared performance intelligence quotients (PIQ)
with verbal intelligence quotients (VIQ). Most studies are in
agreement that VIQ is more affected than PIQ and that the
difference of their means is about 5–8 points [7–10], although
other authors have maintained that the deficits are global in nature
[11,12]. Several studies have performed more detailed analyses of
the specific areas of verbal intelligence that are most affected and
have shown that the impairment of verbal ability appears to be
caused by a defect in verbal working memory for patterns,
numbers and verbal labels [13–16].
Prior to 1960 the cause of cognitive disability in DMD patients
was primarily attributed to functional disabilities or social
environment [17]. The initial evidence of a genetic contribution
to the cognitive defects was provided by the observation of a
greater concordance for IQ among affected brothers. In their
study of 84 siblings with DMD, Ogasawara et al reported a
correlation of 0.80 [18], which was significantly higher than
the median correlation of 0.38 (range 0.0–0.55) identified in a
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meta-analysis of 12 studies of IQ in unaffected male siblings raised
together [19]. Comparisons between DMD and spinal muscular
atrophy (SMA) patients showed that the DMD group had
consistently lower IQ scores and memory skills. Subsequently,
Billard and colleagues confirmed these findings and further
established that DMD boys performed poorly in reading tasks
and in specific memory functions when compared to age matched
SMA patients [13,20]. A significant difference in the frequency of
cognitive impairment is also present between the allelic disorders
Duchenne and Becker muscular dystrophy [21]. Despite consid-
erable evidence that the deficit in intellectual function in DMD has
a significant genetic component a simple relationship between the
degree of cognitive impairment and the severity of muscle
weakness has not been identified, suggesting that these interrelated
phenotypes are under a degree of tissue specific control.
DMD is the clinical manifestation of diverse mutational events
within the DMD gene that result in absence of functional
dystrophin protein. The DMD locus produces at least 7 major
dystrophin isoforms from 7 recognised promoters which exhibit
developmental, regional and cell-type specificity within the central
nervous system. Three full-length isoforms are derived from
unique upstream promoter/first exon sequences Dp427c (also
referred to by some authors as Dp427b), Dp427m, and Dp427p.
At least four shorter mRNA products Dp260, Dp140, Dp116 and
Dp71 are transcribed from more distal promoters located within
downstream introns of DMD (Figure 1) [22]. Among these, Dp71
and Dp140 are particularly abundant in foetal brain, which has
led to the suggestion that they may be of particular significance to
the cognitive defects in DMD [23].
Evidence of a link between mutation location within DMD and
cognitive deficit was based initially on the observation that
deletions of exon 52 were associated with cognitive impairment
[24]. Subsequent studies by Bushby and colleagues reported that
rather than the cognitive impairment being specifically associated
with deletions involving exon 52, deletions localised in the second
half of the gene were more frequently associated with lower IQ
than those in the first half of the gene, but no specific genotype/
phenotype relationship was identified [25,26]. A relationship
between the intellectual impairment and altered expression of the
C-terminal brain-expressed dystrophin isoforms was suggested by
several case reports [27]. The loss of two of the shorter isoforms of
dystrophin, Dp140 and Dp71, has been reported to have the
greatest impact on IQ in DMD [28], whereas there has been no
association reported regarding loss of the Dp260 or Dp116
isoforms. Mutations that affect Dp260 expression have however
been associated with the liability of ophthalmic involvement [29].
Mutations of the promoter of the Dp140 isoform have been
implicated in the risk of cognitive disability [30,31].
There is now substantial evidence that despite their rarity all
patients with mutations involving the Dp71 isoform have severe
intellectual disability [27,32–34] and it has been hypothesised that
as more distal mutations have the potential to affect the expression
of increasing numbers of dystrophin isoforms the severity and
frequency of intellectual disability is related to the effect of
cumulative loss of functional distal isoforms [33].
Over the past 15 years only a minority of the published studies
which have attempted to correlate mutational and IQ data have
reported mutations across the full mutation spectrum seen in the
DMD gene [1,26,32–36]. Here we report correlations between
standardised measures of intelligence and mutational class,
mutation size, mutation location and the cumulative loss of
dystrophin isoforms, focusing in particular on the risk of cognitive
disability for mutations that involve the dystrophin isoform Dp140.
Results
Results for 62 male DMD subjects are provided in Table 1,
including data relating to the identified mutation, the exons
affected by the mutation, the location of a predicted premature
termination codon, the isoform(s) affected as inferred from
mutation location, and results of the neuropsychological assess-
ments. As discussed in detail below (see Subjects and Methods) the
nomenclature system used to relate mutation location to DMD
isoform is depicted in Figure 1. In particular the designations B*
(Table 1, Figure 1) and Dp140utr (in the text) are used for
mutations located in the extended 59UTR of the Dp140 isoform
and which leave the Dp140 promoter intact, whereas the
designations C (Table 1, Figure 1) and Dp140pc (text) areused
to indicate mutations that affect the promoter and/or coding
region of the Dp140 isoform.
All subjects were ascertained based on a clinical diagnosis of
DMD supported by the identification of a mutation in the DMD
gene. Mutation analysis of the DMD gene identified 58 out-of-
frame and 4 in-frame mutations at the genomic level (Table 1)
consistent with the general expectation that mutations associated
with the DMD phenotype produce premature protein truncation
Figure 1. Genomic organisation of alternate dystrophin isoforms. The relationship between the abbreviated nomenclature used for the
isoforms affected by a DMDmutation and the structure of the Dp427m, Dp260, Dp140 and Dp116 isoforms of the dystrophin gene. The black vertical
lines represent the coding exons of the dystrophin gene with exon numbers given below. The positions of the initiator Methionine (ATG),
untranslated region start site (utr) and promoter (Pr) are depicted. The figure demonstrates that exons 45–50 together with the 59 region of exon 51
lie within the 1.041Kbp 59UTR of Dp140 as well as within the coding regions of Dp260 and Dp427. The numbering used is with respect to intron/exon
structure of Dp427m NM_004006.2 and the Human Genome reference sequence of Ensembl build 52 (Dec 2008) implemented in Alamut version 1.5.
doi:10.1371/journal.pone.0008803.g001
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or instability of the dystrophin protein. It is notable that the four
in-frame mutations identified in this cohort have been previously
reported as being associated with DMD and are clustered at the 59
end of the gene, either within or adjacent to the actin binding
domain of the protein [37]. It is inferred that these disrupt critical
domain functions or destabilise the dystrophin protein.
Descriptive IQ Statistics in the SCH DMD Cohort
Significant differences were observed within the SCH cohort
compared with standardised normative values for FSIQ, PIQ and
VIQ (p,0.0001) as assessed by one-sample t-test analysis,
consistent with previous reports [4]. The frequency of intellectual
disability (FSIQ,70) in the SCH study group was 24.2% (15/62).
The reported discordance between VIQ and PIQ was also
identified in this study and had a mean value of 26.7 (N=55,
SD=13.2). This is significantly different from the standardised
mean value of zero (t = 3.768 df = 54, p,0.0005), indicating that
verbal intelligence is more affected than performance intelligence
in children with DMD, consistent with previous published studies
[8,9,12]. Five patients (8%) were noted to have a FSIQ score
above 110, considered to be above average.
Previous studies have reported a high correlation for IQ values
in affected siblings with the same deletion mutation, but a poor
correlation between unrelated affected individuals with the same
deletion. There were 6 pairs of affected brothers, and 7 different
mutations shared by 2 or more unrelated individuals in the SCH
DMD IQ study group. There was a high correlation between
brothers for FSIQ (r=0.98, 95%CI 0.79–0.99, p=0.0008)
consistent with previous studies. In contrast with the published
literature that unrelated boys with the same mutation were often
discordant with respect to intellectual ability [26,38] the SCH
study group data showed that unrelated subjects sharing a DMD
mutation had a high level of correlation for FSIQ (r=0.83,
95%CI= 0.49–0.95, p=0.0008). The FSIQ correlation of 0.98 for
DMD siblings and 0.83 for unrelated DMD-affected individuals
with the same mutation is much higher than that previously
reported for unaffected male siblings reared together (median
correlation of 12 studies 0.38). Rather, it is comparable to the IQ
correlation of male monozygotic twins raised together (0.86) [19].
Association of Mutational Class and Mutation Size with
Cognitive Impairment
To determine if the class of mutational event in the DMD gene
(deletion, duplication, or small point mutation) was correlated with
FSIQ, the study group was categorised by mutation class and the
mean FSIQs compared by 1-way ANOVA. No significant
difference was observed in the mean FSIQ for the different
mutational classes (data not shown). To determine if the size of
genomic DNA involved in the deletion mutations was correlated
with FSIQ, the distribution of FSIQ with respect to both the
number of exons and the kilobase pairs of genomic DNA involved
in the mutation was compared by a Pearson correlation
coefficients but again no significant correlations were identified
(data not shown).
Association of Mutation Location with Cognitive
Impairment
Proximal versus distal mutations. There is published
evidence for a differential effect of proximal versus distal DMD
mutations on cognitive functioning [1,25–26]. The boundary
between proximal and distal groups has been variously set at exon
30 [1] or at exon 45 [25,26]. In order to determine if correlations
could be also be identified in the SCH study group using these
criteria the 62 case group was classified into two subgroups based
on whether the most 39 exon involved in the DMD gene mutation
involved proximal exons only (exons 1–30, or exons 1–45) or
whether they also involved the distal exons (exons 31–79, or exons
46–79). For patients with mutations proximal to exon 30 the mean
FSIQ was 93 and for those proximal to exon 45 the FSIQ was
91.3. For mutations that were located between exons 31–79 the
mean FSIQ was 76.7, and those between exons 46–79 distal
mutations the mean FSIQ was 74. The p values for these
associations were p= 0.002 and p= 0.0007 respectively using a
one-tailed ANOVA for independent samples (Table 2).
Risk of cognitive disability based of mutation location
within Dp140. The foetal brain expressed Dp140 transcript is
atypical in that it has a long 59untranslated region (59UTR) of
1,041 base pairs (Figure 1). Its promoter lies within intron 44 and
first coding exon is exon 51. Subjects with mutations located in the
6K exons encoding the 59UTR of the Dp140 isoform (exons
45–50 together with the portion of exon 51 that lies 59 of c.7381)
could therefore be viewed either as having a protein truncating
mutation of isoforms Dp427 and Dp260 in which exons 45 to 51
are protein coding exons, or alternatively as a mutation within the
59UTR of Dp140. As the effect of deletions and point mutations
limited to the 59UTR of Dp140 could not be confidently
predicted, but protein truncating mutations in DMD coding
exons are of known pathogenicity, subjects with mutations
involving the Dp140 transcript were subclassified into two
groups. The first group contained those mutations restricted to
the 6K exons within Dp140utr which are interpreted principally
as mutations of Dp427 and Dp260 (N=14, listed as ABB* in
Table 1). The second group contained those mutations involving
Dp140pc (N= 11, listed as ABC in Table 1), which have been
previously shown to have a deleterious effect on the expression of
the protein encoded by Dp140 [30,31]. In 4 instances involving
duplication mutations adjacent to exon 45 it was not possible to
unequivocally determine whether the Dp140 promoter had been
included in the duplication and these samples were excluded from
this analysis. A significant difference in mean FSIQ between the 25
subjects in the two groups was identified (p= 0.04, one-tail
unpaired t-test), suggestive that mutations in the promoter and
coding regions of Dp140 have a more profound effect on levels of
protein expression than those in the Dp140 59UTR.
Cumulative effect on FSIQ of mutations in successive
dystrophin isoforms. Given existing information regarding
mutation position and risk of cognitive disability the subset of 58
DMD cases was re-analysed with Dp140utr cases reclassified as
primary affecting Dp427 and Dp260 isoforms (Table 2 model 14,
and Figure 2). A significant effect of grouped isoform involvement
on FSIQ was identified when the data were categorised into 5
groups; Dp427, Dp260+Dp140utr, Dp140pc, Dp116 and Dp71
(df = 4, F= 5.16, p = 0.0014), a model which accounted for a
greater proportion of the variance than an alternative 5 group
model consisting of Dp427, Dp260, Dp140utr+Dp140pc, Dp116
and Dp71 (model 15; df = 4, F= 4.48, p = 0.0034).
A number of other potential models of were also explored using
these data (Table 2). The model that accounted for the greatest
proportion of the variance (F = 13.73, p = 0.0005) was model 5, a 2
group model of consisting of those mutations affecting
Dp427+Dp260+Dp140utr (mean FSIQ 90, S.E. = 2.9) versus
those affecting Dp140pc+Dp116+Dp71 (mean FSIQ 70.4,
S.E. = 3.7). The frequency of FSIQ,100 in the two groups was
67% versus 100%; with the comparable frequency of FSIQ of,70
being 10% versus 39%. Model 5 explained a greater percentage of
the variance in FSIQ than the other alternative two group models
based on assignment of mutations to DMD isoforms, and also
Cognitive Impairment in DMD
PLoS ONE | www.plosone.org 5 January 2010 | Volume 5 | Issue 1 | e8803
accounted for more of the variance than 2 group models based on
the physical location of mutations proximal of exon 30 (F = 10.44;
p = 0.002) or exon 45 (F = 12.82; p= 0.0007). Several three
isoform groups were also assessed, but in no instance were the
mean FSIQs significantly different in all three groups, as assessed
by the Tukey HSD test. It was of interest to note however that the
models which clustered mutations in Dp140utr together with
Dp260 & Dp427 and apart from Dp140pc (models 5, 12 and 13)
explained greater percentage of the variance (average F= 10.4),
than those that did not (average F= 7.2).
Table 2.
Model Model based on Proximal group Intermediate isoform groups (where applicable) Distal group F P Significance
Model 1
[1]
2 structural groups Exons 1–30 Exons 31–79 10.44 0.002 *
Model 2
[25,26]
2 structural groups Exons 1–45 Exons 46–79 12.82 0.0007 *
Model 3 2 isoform groups 427 260, 140utr, 140pc,
116, 71
7.91 0.0068 ns
Model 4 2 isoform groups 427, 260 140utr, 140pc, 116, 71 6.23 0.0155 ns
Model 5 2 isoform groups 427, 260, 140utr 140pc, 116, 71 13.72 0.0005 *
Model 6 2 isoform groups 427, 260, 140utr,
140pc
116, 71 11.13 0.0015 *
Model 7 2 isoform groups 427, 260, 140utr,
140pc, 116
71 7.66 0.0076 ns
Model 8 3 isoform groups 427 260, 140utr, 140pc, 116 71 7.43 0.0014 *
Model 9 3 isoform groups 427, 260 140utr, 140pc, 116 71 6.39 0.0032 ns
Model 10 3 isoform groups 427 260, 140utr, 140pc 116, 71 8.01 0.0009 *
Model 11 3 isoform groups 427, 260 140utr, 140pc 116, 71 6.98 0.002 *
Model 12 3 isoform groups 427, 260, 140utr 140pc, 116 71 9.18 0.0002 **
Model 13 3 isoform groups 427, 260, 140utr 140pc 116, 71 8.43 0.0006 *
Model 14 5 isoform groups 427 260, 140utr 140pc 116 71 5.16 0.0014 *
Model 15 5 isoform groups 427 260 140utr,140pc 116 71 4.48 0.0034 ns
Significance threshold 0.003. ns = not significant, * = 1–10-fold and **.10-fold less than the significance threshold.
doi:10.1371/journal.pone.0008803.t002
Figure 2. Effect of cumulative loss of dystrophin isoforms on FSIQ. A boxplot representation of patient FSIQ data classified by the most 39
dystrophin isoform affected by a mutation. Open circles = patient data points; Vertical lines represent 61 standard deviation of the mean;
boxes = 95% confidence intervals of the mean; horizontal bar =median.
doi:10.1371/journal.pone.0008803.g002
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These data demonstrate that the assignment of mutations to
isoform groups was able to explain greater percentages of the
variance in FSIQ than consideration of the effects of mutations
purely by location, and underscores the importance of the
functional consequences of mutation location as underlying some
of the liability of cognitive disability in DMD.
Discussion
This is among the first reported studies of the effect of mutation
location on the cognitive capacities of a group of DMD patients for
which all mutational classes are represented and where all subjects
have been directly assessed using standard intellectual assessment
tools. The descriptive IQ results for the SCH study group are
representative of previously published studies of cognitive deficits
in DMD, with the mean FSIQ, VIQ and PIQ scores being found
to be approximately one standard deviation (15 IQ points) below
the normative mean of 100, with a VIQ-PIQ deficit of
approximately 7 IQ points. These results indicate that the SCH
DMD cohort data are likely to be comparable with other DMD
cohorts of similar size.
The novel features of this study are that we confirm that the site
of the mutation in the DMD gene is an important determinant of
the risk of cognitive deficit. We also demonstrate here that
classification of the risk of cognitive disability based on structural
features (deletions prior to or after a specific exon) does not explain
as much of the variance in FSIQ in the SCH cohort as does a
classification system based on groups of dystrophin transcript
isoforms affected by the mutation.
Dystrophin gene expression in the central nervous system is
complex and characterised by alternate DMD mRNA transcripts
produced from different promoters together with tissue-specific
alternative mRNA splicing produces a complex pattern of
dystrophin gene related protein expression [39]. The develop-
mental stage, distribution and functions of DMD gene products in
the CNS, although not well characterised, are believed to be
different for each isoform. Differences in the neuropsychological
profiles observed among DMD patients have been postulated to be
due to the number and type of CNS-expressed isoforms affected.
The site of a DMD mutation was found to be clearly related to the
extent of cognitive deficit. The model which best accounted for
this was that where mutations affecting exons 45 to 50 (the
6K exons comprising the noncoding 59UTR of Dp140) were
considered principally as coding exon mutations whose effect is
restricted to Dp260 and Dp427. When categorised in this manner
there was a significant difference in the degree of cognitive
disability when the mutations that affect the coding regions of the
CNS expressed isoforms Dp140pc and Dp71 are clustered
together. The findings that groups of DMD isoforms explains a
greater percentage of the variance in FSIQ needs to seen in the
perspective that the magnitude of that effect is still only of the
order of 13%.
In 2009 Desguerre and colleagues published a long term follow-
up study of a similarly sized cohort of French DMD patients who
had not received steroid treatment [1]. In that study additional
data relevant to cognitive functioning were gathered over many
years of follow-up and when combined explained a larger part of
the variance. Of particular interest was their observation that
mutation location contributes to cognitive disability but not to
motor disability, consistent with the view that that tissue specific
effects are mediated at least in part by the effects of DMD
mutations on the expression of tissue specific isoform expression. A
recent paper by Daoud and colleagues [33] investigated the role of
mutations affecting Dp140 in DMD, and concluded that mild
mental retardation is significantly more frequent with mutations
affecting Dp140. Their analysis included a single classification for
all mutations in the Dp140 transcription unit and is therefore
similar to models 11 and 15 reported in this study.
Although the numbers of patients with Dp71 mutations in this
study are small (N=2), the results for these individuals are typical
of those in the literature where the vast majority of patients with
mutations affecting Dp71 are intellectually disabled [33]. Dp71 is
the major product of DMD in the brain but the function of this,
the shortest dystrophin isoform remains unknown. Two alterna-
tively spliced isoforms of Dp71, both missing exons 71 and 78 and
one also missing exons 72–74 have been identified in human foetal
neural tissue and both are regulated during human neural
development [40]. Dp71 is also associated with glial end feet
and on the basis of this observation Haenggi, et al suggested that it
may contribute to the proper functioning of the cerebrospinal fluid
and blood brain barrier [41]. High level expression of Dp71 has
been noted in neonatal and adult brain, particularly in the
hippocampus and in some layers of the cerebral cortex [42]. Dp71
expression gradually increases from the embryo stage until adult.
Subcellular distribution analysis indicates that Dp71 is mainly
recovered in synaptic membranes, microsomes and to a lesser
extent in synaptic vesicles and mitochondria [43]. Mice deficient
for Dp71 have reduced levels of dystrophin associated proteins in
their brain suggesting that Dp71 has a role in the formation and/
or stabilisation of the dystrophin associated protein complex in the
brain [44].
We also observed a correlation of FSIQ results between related
individuals and also for unrelated patients with the same
dystrophin mutation suggesting that the reduction in FSIQ
observed in boys with DMD has a genetic basis as opposed to
environmental factors. The robustness of this observation is
diminished by the small numbers in the two groups, reflected in
the wide 95% confidence intervals, indicating that this result needs
to be validated by further research.
In summary these data represent one of the largest studies of
FSIQ and mutational data in DMD patients. The correlation of
FSIQ results with the location of the DMD mutation is highly
suggestive that the risk of cognitive deficit is a result of the
cumulative loss of CNS expressed dystrophin isoforms. Further we
have presented data which suggest that mutations affecting the
Dp140 isoform which are located in the 59UTR have a lesser effect
on FSIQ as compared to those affecting the Dp140 promoter or
protein-coding regions.
Materials and Methods
The study protocol was approved prospectively by the SCH
Research Ethics Committee (approval number 04/092QA).
Informed consent for neuropsychometric and mutation testing
was not requested as these are standard items of clinical care
provided to DMD patients in the Sydney Neuromuscular Centre
based on international benchmark standards of clinical practice.
Data analysis was performed on de-identified patient data in a
blinded fashion. Sixty-two boys with Duchenne muscular
dystrophy were identified from within this group who met the
inclusion criteria for neuropsychological testing and had a DMD
gene mutation. (The mutation detection rate for DMD patients
from this institution is 97% indicating that there is negligible bias
in patient selection based on the availability of mutation data). Of
these 62 boys, dystrophin isoform assignments could be made for
58 and comprehensive IQ data profiles were available for 53 of
these 58. For the remaining 5 subjects partial data profiles were
available. The comprehensively studied subjects included six pairs
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of brothers with the same mutation, and 9 mutations shared by 2
or more unrelated individuals. The mean age at the time of
assessment was 9.7 (SD=2.9, range = 4.25 to 14.83) years.
Intellectual Assessment
Intelligence testing was performed and the data analysed by a
registered clinical psychologist (GAB). Subjects were examined
using the Wechsler Intelligence Scales. This consisted of either the
Wechsler Preschool and Primary Scale of Intelligence [WPPSI-R]
or Wechsler Intelligence Scale for Children [WISC-III], depend-
ing on the age at assessment. Children up to the age of 6 years
were assessed using the WPPSI-R whereas children over 6 years of
age were assessed by the WISC-III.
Mutation Analysis
Dystrophin gene mutation analysis was performed as part of the
study of the SCH B/DMD cohort as previously described [45].
Mutations are described using HGVS nomenclature and the
positions of mutations and predicted pathogenic events are
reported with respect to reference sequence NM_004006.2 for
the Dp427m isoform. Mutations were checked by reference to the
Leiden Muscular Dystrophy pages DMD gene reading frame-
checker (http://www.dmd.nl/) and analysis with the online
sequence variant checking software Mutalyzer (http://eu.liacs.
nl/mutalyzer/). The base pair location of the novel Premature
Termination Codon (PTC) was determined for out of frame,
nonsense and frame-shifting point mutations as the final base of
the codon using the output from Mutalyzer and confirmed by
visual inspection of the dystrophin gene sequence in Alamut 1.5
(Interactive Biosoftware). For in-frame mutations pathogenicity
was inferred from published data of the effects of the mutation on
dystrophin protein functional domains.
Dystrophin mutations were assigned to mRNA isoforms as
follows (Figure 1). Mutations were used to determine the position
of PTCs as outlined above. Mutations were assigned to isoform
Dp427m (‘A’) if their PTCs were located 59 of the first base of the
ATG of the Dp260 isoform at c.4072-296. Mutations were
deemed to affect both Dp427 and Dp260 (‘AB’) if the PTC lay
between ATG of Dp260 at c.4072-296 and exon 1 of Dp140 at
c.6438+61447. Mutations were deemed to affect Dp427, Dp260
and Dp140utr (‘ABB*’) if their PTCs were located between the
noncoding exon 1 of Dp140 at c.6438+61447 and 59 of the ATG
of Dp140 at c.7381 and left the Dp140 promoter intact. Mutations
that removed the Dp140 promoter and had a PTC located in the
coding region of Dp140 between the initiator ATG at c.7381 and
that of Dp116 at c.8218-790 were deemed to affect isoforms
Dp427m, Dp260 and Dp140 (‘ABC’). Four isoforms Dp427,
Dp260, Dp140 and Dp116 (‘ABCD’) were deemed to be involved
if a PTC was located between the initiator ATGs of Dp116 at
c.8218-790 and Dp71 at c.9225-5813. All 5 isoforms (‘ABCDE’)
were deemed involved if a PTC was located distal to the ATG of
Dp71 at c.9225-5813.
For the Dp140 isoform the presence or absence of its unique
first coding exon and adjacent 59 promoter region was determined
in all patients with a deletion mutation where the last deleted exon
was exon 44, or the first deleted exon was exon 45. The integrity of
the Dp140 unique first exon was established as described in Lidov
et al. [46]. The integrity of the Dp140 promoter was determined by
amplification of microsatellite IVS44SK12, as described by
Kochling et al. [47]. Dystrophin exon 8 was co-amplified as a
control, but as this technique is not quantitative the results from 4
subjects (16exon 45 duplication and 36exon 45–52 duplications)
were not included in all parts of the analysis.
Statistical Analyses
For the analysis of the cognitive profile of the FSIQ study group,
statistical analyses were performed using one sample t-test
compared to normative Wechsler Scale mean values and Pearson
correlation coefficient for patients having the same dystrophin
mutation. The likelihood of a normal distribution of values was
assessed using the D’Agostino & Pearson omnibus normality test.
In each case p,0.05 was considered significant. The Pearson
correlation coefficient was calculated to determine correlations
between FSIQ results for DMD sib-pairs and unrelated pairs with
the same dystrophin mutation and also for correlations between
FSIQ and the number of exons deleted in deletional cases of
DMD. The paired Student’s t-test was used to determine the
similarity of the differences in paired FSIQ data for sib-pairs
compared to unrelated–pairs with the same dystrophin mutation.
One way ANOVA was used to assess differences between the 3
major mutational classes associated with DMD and FSIQ. For the
hypothesis that the loss of groups of more distal isoforms
cumulatively affected FSIQ a one way ANOVA was performed
on the classification methods and amount of the variance
accounted for by each model was quantified using an F statistic.
A Bonferroni correction for significance was applied to take
into account multiple ANOVA tests performed and the adjusted
threshold for significance set at 0.05 (prior significance)/15 (the
number of models tested) = 0.003.
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